| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7687075 | SALIX PHARMS | Colonic purgative composition with soluble binding agent |
Jun, 2028
(4 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5616346 | SALIX PHARMS | Non-aqueous colonic purgative formulations |
May, 2013
(10 years ago) | |
Osmoprep is owned by Salix Pharms.
Osmoprep contains Sodium Phosphate, Dibasic, Anhydrous; Sodium Phosphate, Monobasic, Monohydrate.
Osmoprep has a total of 2 drug patents out of which 1 drug patent has expired.
Expired drug patents of Osmoprep are:
- US5616346
Osmoprep was authorised for market use on 16 March, 2006.
Osmoprep is available in tablet;oral dosage forms.
Osmoprep can be used as for cleansing the bowel in preparation for colonoscopy, in adults 18 years of age or older.
The generics of Osmoprep are possible to be released after 22 June, 2028.
Market Authorisation Date: 16 March, 2006
Treatment: For cleansing the bowel in preparation for colonoscopy, in adults 18 years of age or older
Dosage: TABLET;ORAL
How can I launch a generic of OSMOPREP before it's drug patent expiration?
More Information on Dosage
OSMOPREP family patents
